Abstract | Traumatic brain injury (TBI) is a leading cause of mortality and morbidity both in civilian life and on the battlefield worldwide. Survivors of TBI frequently experience long-term disabling changes in cognition, sensorimotor function and personality. Over the past three decades, animal models have been developed to replicate the various aspects of human TBI, to better understand the underlying pathophysiology and to explore potential treatments. Nevertheless, promising neuroprotective drugs that were identified as being effective in animal TBI models have all failed in Phase II or Phase III clinical trials. This failure in clinical translation of preclinical studies highlights a compelling need to revisit the current status of animal models of TBI and therapeutic strategies.
1
. TBI is the leading cause of death and disability for people under the age of 45 years 2 . Indeed, worldwide, 10 million deaths and/or hospitalizations annually are directly attributable to TBI and an estimated 57 million currently alive people have experienced such brain injury 2 . TBI is not a single pathophysiological event but a complex disease process 3 
, and it causes structural damage and functional deficits that are due to both primary and secondary injury mechanisms 4 . The primary injury is the result of the immediate mechanical disruption of brain tissue that occurs at the time of exposure to the external force and includes contusion, damage to blood vessels (haemorrhage) and axonal shearing, in which the axons of neurons are stretched and torn 5, 6 . Secondary injury evolves over minutes to months after the primary injury and is the result of cascades of metabolic, cellular and molecular events that ultimately lead to brain cell death, tissue damage and atrophy [7] [8] [9] . Many biochemical derangements that are responsible for secondary injury have been identified. These include glutamate excitotoxicity, perturbation of cellular calcium homeostasis, increased free radical generation and lipid peroxidation, mitochondrial dysfunction, inflammation, apoptosis and diffuse axonal injury (DAI) 10 . As highlighted above, collectively, the cascade of secondary injury events culminates in neuronal, endothelial and glial cell death and white matter degeneration 7, 11 . Cell death occurs within minutes after injury and extends over a period of days to months 11, 12 . Necrotic and apoptotic cell death have been identified in contused areas, the injury boundary zone and subcortical regions 12, 13 , and apoptosis coincides with progressive atrophy of grey and white matter following TBI 7 .
The relative contributions of cell death and sublethal neurobiological derangements to post-traumatic morbidities remain to be determined. Many sub-lethal cellular events and systemic insults, including hypoxia and hypotension, may in concert ultimately lead to cell death without timely intervention. Both acute cell death and delayed apoptosis have an important role in mediating functional deficits after TBI. However, even mild TBI without notable cell death can lead to cognitive deficits, which are probably associated with DAI, as indicated by studies in humans 14, 15 , rodents 16 and swine 17 . These findings suggest that multifocal axonal and myelin abnormalities also contribute to post-traumatic cognitive impairments.
As the primary injury occurs immediately after the moment of trauma, it can only be preventable (for example, through the use of a seat belt or helmet). By contrast, the elongated nature of secondary injury development provides a window of opportunity for therapeutic intervention, which may prevent and/or reduce secondary brain damage and improve long-term patient outcome. To date, however, promising results from preclinical studies of potential TBI treatments have not been translated into successful outcomes in clinical trials. The Diffuse axonal injury (DAI) . DAI is characterized by impaired axoplasmic flow that progresses to axotomy and is typically identified by the presence of the amyloid-β precursor protein, as revealed by immunohistochemical staining.
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pathophysiological heterogeneity observed in patients with TBI, the lack of adequate pharmacokinetic analyses to determine optimal doses of potential therapies and the administration of compounds outside the therapeutic window may have led to the clinical trial failures 18 . The pathophysiological heterogeneity observed in patients with TBI may arise from the location, nature and severity of the primary injury and the effects of other factors and pre-existing conditions, including but not restricted to age, health, sex, medication, alcohol and drug use, and genetics 19 . Animal models of TBI are each designed to produce a relatively homogeneous type of injury, with age, sex, genetic background and the injury parameters all well controlled. Thus, any one animal model may not be able to fully recapitulate all the aspects of secondary injury development that are observed in human TBI, and this may in part explain why drugs that showed promise in preclinical studies failed in clinical studies 9 . Undoubtedly, however, animal models are essential for studying the biomechanical, cellular and molecular aspects of human TBI that cannot be addressed in the clinical setting, as well as for developing and characterizing novel therapeutic interventions. New and existing animal models of TBI need to be developed and modified, respectively, to develop new therapeutic strategies and to traverse the therapeutic gap between preclinical studies and patient medical care.
This Review aims to provide a broad overview of current knowledge of animal models of TBI, to identify the issues and challenges related to studying therapeutic strategies in preclinical studies and to highlight research strategies for improving animal models and therapeutic efficacy.
Box 1 | Simplified pathophysiology of TBI
In traumatic brain injury (TBI), the primary injury, which is the direct result of the external force, involves mechanical tissue deformation (see the figure) . This leads to secondary injury initiation involving diffuse neuronal depolarization and release of excitatory neurotransmitters (glutamate and aspartate) 197, 198 , which bind to glutamate receptors and induce a massive influx of calcium 199 . Calcium activates calcium-dependent phospholipases, proteases and endonucleases that degrade lipids, proteins and nucleic acids (not shown). Calcium sequestration in mitochondria leads to calcium disturbance, energy deficits, free radical formation and initiation of apoptosis 200, 201 . Increased formation of oxygen and nitrogen reactive species oxidizes lipids, proteins and nuclei acids after TBI 202 . TBI upregulates many transcription factors, inflammatory mediators and neuroprotective genes but downregulates neurotransmitter receptors and release mechanisms 203 . Increased expression of detrimental cytokines and chemokines induces brain oedema, blood-brain barrier damage and cell death 204 . The result of these complex cascades after TBI is eventually cell damage and death, which cause functional deficits. Substantial experimental and clinical data have accumulated over the past decade indicating that the adult brain is capable of substantial structural and functional reorganization after injury, which may contribute to spontaneous functional recovery. Interventions targeting secondary injury mechanisms and modulating neuroplasticity promote functional recovery in animal models of TBI. Solid lines represent established interactions or pathways, whereas dashed lines represent possible interactions or pathways.
Modified NSS
The modified NSS (neurological severity score) is a composite of motor, sensory, reflex and balance tests for use in rats.
Animal models of TBI In view of the heterogeneous nature of the clinical situation in TBI, numerous animal models of such injury have been developed. Although larger animals are closer in size and physiology to humans, rodents are mostly used in TBI research owing to their modest cost, small size and standardized outcome measurements, among other reasons
. Whereas early models of TBI addressed the biomechanical aspects of brain injury [20] [21] [22] , more-recent models have been targeted at improving our understanding of the detrimental, complex molecular cascades that are initiated by head trauma. Among these more-recent models, four specific models are widely used in research: fluid percussion injury (FPI) 23 , controlled cortical impact (CCI) injury 24, 25 , weight-drop impact acceleration injury 26 and blast injury 27, 28 Fluid percussion injury models. In FPI models, an insult is inflicted by a pendulum striking the piston of a reservoir of fluid to generate a fluid pressure pulse to the intact dura through a craniotomy, which is made either centrally around the midline between bregma and lambda 30 , or laterally over the parietal bone between bregma and lambda 31 . The percussion produces brief displacement and deformation of brain tissue, and the severity of injury depends on the strength of the pressure pulse 31 . FPI models replicate clinical TBI without skull fracture 8 . Moderate-to-severe TBI in humans is often associated with skull fracture and contusions across multiple gyri 32 , features that cannot be replicated in this model. FPI can, however, replicate intracranial haemorrhage, brain swelling and progressive grey matter damage, which are all pathophysiological hallmarks of human TBI 33 . On the basis of the position of the craniotomy away from the sagittal suture, FPI models can be divided into midline (centred on the sagittal suture), parasagittal (<3.5 mm lateral to midline) and lateral models (>3.5 mm lateral to midline) 31, [34] [35] [36] . The midline FPI model of TBI was initially developed for use in cats and rabbits [37] [38] [39] , subsequently adapted for use in rats 23, 30 and then modified to produce the lateral FPI (LFPI) model in rodents 31, 40 . In all, FPI has been used for studying TBI pathophysiology and pharmacology in cats 41 , rabbit 38 , dogs and sheep 42 , rats 43 , mice 40, 44 and pigs 45, 46 . The LFPI model is one of the most widely used TBI animal models 8 . In rats, LFPI produces a combination of focal cortical contusion and diffuse subcortical neuronal injury (including injury in the hippocampus and thalamus), which occurs within minutes of the impact and progresses to a loss of neurons by 12 hours but does not markedly expand into other brain regions by 7 days post-injury 47 . The contused cortex beneath the injury site enlarges over weeks to become a cavity lined with glia and continues to expand up to 1 year post-injury owing to ongoing cell death 48 . Over days to months, progressive degenerative cascades persist in selectively vulnerable brain regions, including the ipsilateral hippocampus, thalamus, medial septum, striatum and amygdala 8, 47, 49 . LFPI produces neurobehavioural and cognitive deficits (such as difficulties with movement and memory) that are commonly seen in patients with TBI 50, 51 . Cognitive dysfunction and neurological impairments persist for more than a year following severe LFPI 52 . However, FPI models have high mortality compared with other models, which is probably due to the brainstem-compromised prolonged apnea 5 . The site of craniotomy is crucial in determining the extent and location of tissue injury produced by LFPI in rats 35 . Indeed, careful attention should be paid to where the craniotomy is made to increase the reliability and reproducibility of this model. LFPI inflicts primarily unilateral cortical damage, rarely involving the contralateral cortices and brainstem, whereas midline and parasagittal FPI causes bilateral cortical alterations associated with direct axial movement of the lower brainstem 5 . The degree of cortical damage highly depends on both craniotomy position and injury severity 36 . The FPI model allows minimal biomechanical control of the insult, with the height of pendulum as the only adjustable mechanical parameter. A microprocessor-controlled, pneumatically driven instrument was developed to improve reproducibility and to address operational concerns associated with the use of the standard FPI Box 2 | Functional outcome testing in animal models of TBI Motor function is mediated by a complex system of neural networks originating in the brain cortex and terminating in skeletal muscles 160 . The association cortex, sensorimotor cortex, subcortical nuclei, cerebellum and brainstem all communicate with each other to send a signal through the spinal cord to coordinate movement 160 . Deficits caused by traumatic brain injury (TBI) result from disruption of the complex motor pathways and sensorimotor integration, and therefore most of the described tests for assessing the outcome of such injury in animal models are sensorimotor in nature 160 . Widely used sensorimotor function tests include the cylinder test, rotarod test, grip strength tests, skilled forelimb reaching and staircase tests 160 . The neurological severity score (NSS), which takes into account motor functions and behaviour, is widely used to assess closed head injury in rodents 89, 91 . In addition, the modified NSS is a very useful tool for evaluating neurological functional deficits in rats after unilateral brain injury 205, 206 . TBI in humans frequently leads to cognitive dysfunction, the degree of which often depends on the injury severity 207 . Cognitive dysfunction has been described in the controlled cortical impact injury, lateral and midline fluid percussion injury, blast and impact acceleration animal models of TBI 16, 81, 91, 190, 191, 208 . Commonly used tests of cognition in rodents include the Morris water maze, freezing response test, memory task and object recognition test 160 . Some more complex behavioural tests have also been developed in experimental TBI research to mimic the complex personality and psychological disturbances in patients with TBI. Anxiety-like tests include the elevated-plus maze, emotional and exploratory activity, and the open field tests 65, [209] [210] [211] . Depression, which is a common clinical problem after TBI, has not been fully studied in animal models, although there are a few reports using the forced swimming test to assess depression-like behaviour 211, 212 . Functional tests have rarely been developed or performed in large animals after TBI. Recently, a wide range of neurobehavioural functional tests, including open field testing (executive function), the glass barrier task (visual-based problem solving), the food cover task (olfactory-based problem solving) and the balance beam (motor), have been performed in the neonatal pig following closed head injury 132, 213 . Further development or use of functional tests in large animals is warranted to verify the safety and efficacy of promising treatments that are effective in small animal models of TBI before clinical trials are initiated. device in rats 53 . With this new device, the impact pressure and dwell time could be precisely controlled, thus reducing variation between trials. This approach produced acute and chronic TBI features similar to those reported in the LFPI literature, as quantified by histological changes, structural changes seen with MRI and chronic behavioural sequelae. One final point to note is that although the LFPI model has been popular for studying neuronal cell death mechanisms in TBI, there is a recent resurgence of interest in midline FPI because of the increased interest in diffuse brain injury associated with sport and blasts 54, 55 .
Controlled cortical impact injury model. The CCI model uses a pneumatic or electromagnetic impact device to drive a rigid impactor onto the exposed, intact dura and mimics cortical tissue loss, acute subdural haematoma, axonal injury, concussion, blood-brain barrier (BBB) dysfunction and even coma 24, 25, 53, 56, 57 . It has been applied to ferrets 25 , rats 24 , mice 56 , swine 58 and monkeys 59 . The controlled impact is delivered to the intact dura through a unilateral craniotomy lying most often between bregma and lambda, which causes deformation of the underlying cortex 24 . A comprehensive neuropathological evaluation of the CCI TBI model revealed that the associated damage can be widespread, including acute cortical, hippocampal and thalamic degeneration 60 . The advantage of this injury model over other TBI models is the ease with which mechanical factors, such as time, velocity and depth of impact, can be controlled.Thus, it may be more useful than the FPI model for biomechanical studies of TBI 5, 61, 62 . An additional strength of the CCI model, when compared with models involving gravity-driven devices, is the lack of risk of a rebound injury. The histopathological severity of CCI injury rises with increasing cortical deformation and impact velocity, permitting adjustment of the injury severity appropriate for specific experimental requirements 63, 64 . The functional deficits observed in CCI injury in mice and rats, such as cognitive impairments (which have been detected in the Morris water maze (MWM) test), are highly related to both the depth of deformation and the velocity of the impact [65] [66] [67] . These cognitive deficits persist up to 1 year post-CCI injury and may be associated with brain atrophy 68, 69 and a progressive decline in cerebral blood flow 70 . CCI injury can also cause deficits in emotional behaviour, as quantified in the forced swim test, elevated-plus maze and prepulse inhibition of acoustic startle in mice 70 . Cognitive deficits increase in relation to injury severity but emotional deficits do not, suggesting that the threshold for emotional changes after experimental TBI is low 65 . The swine CCI model generates a reproducible injury with pathological features similar to human TBI 58, 71 . Despite its cost and complexity, this large animal model offers the opportunity to collect physiological data following brain injury in an environment similar to the intensive care unit and thus may facilitate translation of animal data into clinical practice.
Penetrating ballistic-like brain injury models. Penetrating ballistic-like brain injury (PBBI) is caused by transmission of projectiles with high energy and a leading shockwave, which produces a temporary cavity in the brain that is many times the size of the projectile itself 72 . The outcome in this model is directly related to the anatomical path of the projectile and the degree of energy transfer [72] [73] [74] . In the past, the experimental PBBI studies that were most relevant to gunshot wounds were done in cats using a penetrating missile model 75, 76 . A rat model of penetrating brain injury has been characterized and shown to produce cognitive impairment 72, 77 . It induces marked white and grey matter damage, brain swelling, seizures, cortical spreading depression and neuroinflammation, and results in sensorimotor impairment 74, 78 . Therapeutic treatments, including dextromethorphan and human amnion-derived multipotent progenitor cells, have recently been evaluated in this model 79, 80 .
Recently, several new PBBI rodent models have been developed [81] [82] [83] . A novel non-fatal model for low-velocity PBBI has been established in rats involving a modified air rifle that accelerates a pellet 82 . This PBBI causes cavity formation, white matter degeneration, haemorrhage, oedema and gliosis. As mentioned above, bullets or shrapnel that penetrate the brain with high energy produce a temporary cavity in the brain, which can be many times the size of the projectile itself 84 . To mimic the ballistic effect of such an injury, a PBBI rat model has been established to characterize immediate and subacute (up to 7 days) changes in intracranial pressure (ICP) 83 . BBB permeability, brain oedema formation and enduring motor and cognitive deficits have been identified in a unilateral frontal PBBI in rats 81, 85 . Neurofunctional assessments revealed that motor deficits (as detected on the balance beam and in the rotarod task) and cognitive deficits (impairments in spatial learning in the MWM test) correlated with injury severity.
Several pathophysiological characteristics of PBBI are similar to those reported in other brain trauma models, including the presence of hemispheric swelling, increased ICP, remote white matter injury and neuroinflammation 73, 78 . However, compared with other TBI models, PBBI causes extensive intracerebral haemorrhage throughout the primary lesion owing to the penetrating nature of the injury and the temporary cavity that it forms. The PBBI model captures several unique temporal aspects of a ballistic brain injury and may serve as a highly relevant model of moderate-to-severe brain trauma for mechanistic studies and for the evaluation of therapeutic interventions.
Weight-drop TBI models. In weight-drop models, the skull is exposed (with or without a craniotomy) to a free falling, guided weight 50 . Injury severity in these models can be altered by adjusting the mass of the weight and the height from which it falls. TBI, traumatic brain injury. -, does not replicate the condition observed in humans; +/-, might replicate the condition observed in humans; +, replicates the human condition to some degree; ++, high fidelity to the human condition.
Neurological severity score (NSS). The NSS is a reliable tool for evaluating neurological damage in closed head trauma in mice and rats, and assesses both motor function and behaviour.
Phosphorylated tauopathy
This is the accumulation of hyperphosphorylated tau protein (a highly soluble microtubule-associated protein), which causes the formation of neurofibrillary tangles. These tangles are a pathological hallmark of tauopathies, which are a group of diseases including Alzheimer's disease, frontal temporal dementia with Parkinsonism and corticobasal degeneration.
In Feeney's weight-drop model, the weight is delivered to the intact dura through a craniotomy, which causes a cortical contusion 86 . Morphologically, these injuries progress from haemorrhages in white matter directly under the contused cortex during the first few hours after injury to the development of a necrotic cavity by 24 hours. The cavitation appears to expand over the subsequent 2 weeks 86, 87 . Although most functional recovery occurs in the first 2 weeks after trauma in rats with severe contusions, deficits can persist beyond 90 days 86, 88 . Shohami's group later introduced a rodent model for closed head injury (CHI) using a weight-drop impact delivered to one side of an unprotected skull in rats 89, 90 or mice [91] [92] [93] while the head was placed on a hard surface. The mouse CHI model was described in detail and involved a standardized weight-drop device that delivered a focal blunt injury to the unprotected skull 93 . The resulting impact caused neurological impairment and breakdown of the BBB. The neurological severity score (NSS) assessment was performed to evaluate neurological impairment in motor function, alertness and seeking behaviour, and it was found that the score highly correlated with the severity of brain injury. 26 developed a model of DAIMarmarou's impact acceleration model -to mimic diffuse TBI in humans, which is typically caused by falls or motor vehicle accidents 26 . DAI is common in humans and experimental animals with TBI 96, 97 , and in this model, the trauma device consists of a sectioned brass weight set that falls freely from a designated height through a Plexiglas tube. In anaesthetized rats with skull exposure made by a midline incision, a stainless steel disc is mounted with glue to the skull midline between lambda and bregma to prevent skull fracture. The rats are then placed on a foam bed and subjected to the impact by dropping the brass weight onto the stainless steel disc. Death in this model is primarily caused by respiratory depression, and mechanical ventilation after the impact greatly reduces the mortality rate after severe injury 26, 84 . Marmarou's model is characterized by widespread and bilateral damage of neurons, axons, dendrites and microvasculature as well as extensive DAI, particularly in the corpus callosum, internal capsule, optic tracts, cerebral and cerebellar peduncules, and the long tracts in the brainstem 84 . It is also characterized by motor and cognitive deficits such as difficulties with beam walking and memory 98, 99 , similar to those observed after FPI and CCI, and the extent of these deficits correlates with injury severity 26, 89, 100 . One disadvantage of the weight-drop models is the relatively high variability in injury severity. However, Marmarou's weight-drop procedures are inexpensive, easy to perform and capable of producing graded DAI that closely mimics that seen in human TBI.
Previously available rodent models of CHI do not reproduce the frontal impact commonly encountered in motor vehicle and sports accidents 101 . A new rat model of CHI has been developed, by modification of the Marmarou's impact acceleration model, to investigate these scenarios 101 . In the new model (called the Maryland model), the impact force is applied to the anterior part of the cranium and produces TBI by causing anterior-posterior plus sagittal rotational acceleration of the brain inside the intact cranium 101 . The animals are characterized by an absence of cortical contusions, skull fractures, prolonged apnea and an absence of mortality but demonstrate petechial haemorrhages and DAI. Neurobehavioural dysfunction, manifesting as reduced spontaneous exploration, persists for more than 1 week. Additional study will be needed to further characterize this model. 102, 103 . To elucidate the effects of primary blast waves on the CNS, various animal models of blast TBI have been established, mainly in rodents 27, [104] [105] [106] [107] and swine 108, 109 . Using a compression-driven shock tube to simulate blast effects, the physiological, neuropathological and neurobehavioural consequences of blast exposure were assessed and the effect of a Kevlar thoracic protective vest on acute mortality in rats and on the frequency of TBI and DAI in those animals that survived was also evaluated 107 . The Kevlar vest, which encased the thorax and part of the abdomen, greatly reduced air blast mortality and also ameliorated the widespread axonal fibre degeneration, indicating that shock tube-generated blast causes TBI in rats, in part through systemic effects, including hypotension and hypoxaemia, which are possibly evoked by blast-induced lung injury and/or haemorrhage 110 . A blast-induced TBI rat model that mimics real blastinduced mild TBI seen in recent military conflicts has been developed 111 . Non-impact blast injury exhibits an interesting pathophysiology, which is characterized by diffuse cerebral brain oedema, extreme hyperaemia and a delayed vasospasm (these features are seen in animal and human blast brain injury) 112 . DAI was the most prominent feature during the initial 2 weeks following blast exposure in rats with body shielding 113 . It has been found that exposure of the head alone to a severe explosive blast causes significant neurological dysfunction 114 . Importantly, even exposure of rats to a low level blast increases ICP and causes cognitive deficits 115 . Although functional deficits due to blast exposure are the principal health problem in modern warfare, most of the available blast models focus on tissue destruction rather than functional deficits 110, 111, 113, 116 . A recent report indicates that even mild blast brain injury caused prolonged behavioural and motor abnormalities in mice, including deficits in social recognition, spatial memory and motor coordination, and shielding of the torso ameliorated axonal injury and the behavioural deficits 117 . Clearly, further research is necessary to address whether and how blast TBI, in particular multiple exposures to a low-level blast, can lead to long-term functional deficits.
Models of blast TBI.
It has been demonstrated that blast-exposed mice show phosphorylated tauopathy, myelinated axonopathy, microvasculopathy, chronic neuroinflammation and neurodegeneration in the absence of macroscopic Biomarkers A biomarker is a specific biochemical, molecular, anatomical or physiological characteristic that is used to measure or indicate the presence or progress of disease or the effects of treatment.
Glasgow coma scale
(GCS). The GCS is a standardized scale that is used to measure the level of consciousness, to assess the degree of brain impairment and to identify the seriousness of injury in relation to outcome after TBI. The score is determined by summing the ratings of how the patient responds to certain standard stimuli by opening their eyes, giving a verbal response and giving a motor response. A high score of 13 to 15 indicates a mild brain injury, a score of 9 to 12 reflects a moderate brain injury and a score of 3 to 8 reflects a severe brain injury.
Glasgow outcome scale
(GOS). The GOS is an outcome score in which individuals with TBI are assigned to one of five categories: dead, vegetative state, severe disability, moderate disability or good recovery. The extended GOS (GOSe) provides more detailed categorization into eight categories by subdividing the categories of severe disability, moderate disability and good recovery into lower and upper categories.
tissue damage or haemorrhage 94 . Head immobilization during blast exposure prevented blast-induced learning and memory deficits, indicating that head rotation may play an important part in generating these deficits. It has become increasingly clear that brain pathology, the underlying mechanisms and potential biomarkers associated with primary blast exposures may be different from those imposed by focal mechanical head trauma 118 . It should be noted that the location of animal placement in relation to the shock tube (that is, inside, outside or near the exit of the tube) has an important role in the biomechanical loading on the animal and thereby alters the injury type, its severity and the probability of lethality 119 . Considering the variations in the current blast injury models, comparison of the results between different laboratories is virtually impossible. Thus, the further design, characterization and implementation of relevant standard experimental blast models is of particular importance for the elucidation of the mechanisms of blast injury, the identification of biomarkers and, eventually, the development of strategies for mitigating blast-induced brain injury.
Mild TBI models. Mild TBI constitutes most of the 1.7 million TBIs that are reported in the US annually 120 . Repeated mild TBI, a form of CHI, commonly occurs in contact sports (for example, in boxing, hockey, soccer and American football), child abuse victims and modern military personnel 121, 122 . Growing evidence indicates that repeated brain concussion can result in cumulative and long-term behavioural symptoms, neuropathological changes and neurodegeneration 120, 123 . Several models have been developed to mimic the clinical consequences of repeated mild TBI 122 , including the weight-drop model 124, 125 , the mouse blast TBI model 104 , the rat FPI model 126 and the swine CHI model 127 . Marmarou's impact acceleration model has been modified to allow repeated head impacts in lightly anaesthetized mice 128 . This method does not require scalp incision and protective skull helmets. Mice spontaneously recover the righting reflex without evidence of seizures and paralysis, and skull fractures and intracranial bleeding are rare. Minor deficits in motor coordination and locomotor hyperactivity recover over time. Mild astrocytic reactivity and increased phospho-tau levels occur without BBB disruption, oedema and microglial activation. This new animal model is suitable for the screening of new therapies for mild concussive injuries.
A single mild LFPI induces short-term behavioural and neuropathological changes in the rat 129 , whereas repeated mild LFPI in rats causes cumulative long-term behavioural impairments, neuroinflammation and cortical neuron loss 130 . Interestingly, sub-concussive brain injury induces acute neuroinflammation in the absence of behavioural impairments in rats after TBI 131 . In an immature large animal model of TBI in neonatal piglets, two head rotations following injury led to poorer outcomes, as assessed by neuropathology and neurobehavioral functional outcomes, than did a single rotation 132 . White matter injury increased in the repeat rotation group compared with the single injury group. More importantly, an increase in injury severity and mortality was observed when the head rotations occurred 24 hours apart compared with 7 days apart. Worsening performance on the cognitive composite score was associated with increasing severity of white matter axonal injury.
These findings in animal models suggest that repeated mild TBI occurring within a short period can be catastrophic or fatal and are consistent with findings in human patients who have experienced repeated brain concussions. These models will provide further insights into sports-and combat-related repeated concussions that should help healthcare providers make better decisions about allowing individuals with TBI to return to their duties and identify people who may be at enhanced risk for TBI.
Limitations of current animal models Physiological differences. Although there is substantial similarity in the physiology of non-human mammals (in particular rodents) and human brains, it is clear that notable differences exist between these groups in terms of brain structure and function, including brain geometry, craniospinal angle, gyral complexity and white-togrey matter ratio 50, 133 . These structural characteristics may lead to substantially different responses to trauma of comparable severity or type from species to species 134 . This situation becomes even more complex, as a number of investigations have described profound differences between behavioural and histopathological responses to TBI among different rat strains 135, 136 and mouse strains 137 . There is also evidence for sex differences in outcome after TBI in animals and humans 138, 139 . Female sex is often associated with a lower rate of comorbidities and complications after TBI than male sex 139 , and experimental animal studies suggest that female sex hormones may have a neuroprotective effect 139, 140 . Current clinical evidence indicates that the female hormone progesterone improves the neurological outcome of patients with TBI 141 . However, controversy exists regarding the effect of sex differences on clinical TBI outcome 139, 142 . In addition to sex hormones, many other differences between sexes, including differences in pre-injury comorbidities, brain function and metabolism, may affect outcome 142 . As most experimental TBI studies have been conducted in male animals, further studies on sex differences in response to TBI and treatment are clearly warranted.
Many investigators studying TBI models do not rigorously measure physiological variables before and after TBI, including pCO 2 , pO 2 , pH, blood pressure and brain temperature. These variables are extremely important in determining pathophysiological responses to injury and therapy. Indeed, this is one of the shortcomings of the TBI field and should be strengthened because of the importance of these variables on acute and long-term outcomes.
Injury severity measurement. Acute assessment of injury severity is critical for the diagnosis, management and prognosis of TBI. Currently, in TBI clinical trials, the Glasgow coma scale (GCS) is the primary means for patient selection, and the Glasgow outcome scale (GOS), Erythropoietin (EPO). EPO is a glycoprotein hormone secreted by the kidney in adult mammals and by the liver in the fetus; it acts on stem cells of the bone marrow to stimulate red blood cell production (that is, erythropoiesis).
Tissue plasminogen activator
(tPA). tPA is an enzyme that catalyses the conversion of plasminogen to plasmin and is used to dissolve blood clots rapidly and selectively, especially in the treatment of heart attacks and ischaemic stroke.
or its eight-point extended version (GOSe), remains a primary method for assessing outcomes 143, 144 . Although the severity of injury can be determined by an NSS evaluation conducted 1 hour after CHI in mice and rats 93, 145 , there has been no common scoring system for injury severity that has been widely adopted for animals based on a brief neurological examination such as the GCS in patients with TBI. Thus, the mechanical injury parameters in combination with histological evidence and functional tests are the most reliable measurements for classification of experimental TBI into mild, moderate and severe levels 8, 65, 93, 146 . Scoring systems based on mechanical parameters may be specific only for a particular laboratory as most injury devices are custom-made and show subtle differences in design and operation. Additionally, small shifts in craniotomy position produce differences in cognitive performance, hippocampal cell loss and reactive astrogliosis in rats after LFPI 36 , and this variability makes the comparison of experimental findings from different laboratories challenging. Moreover, the post-traumatic sequelae after mild TBI without overt morphological damage and severe TBI with high mortality have not been comprehensively studied in animal models.
MRI is especially useful for non-invasively detecting white matter reorganization after brain injury 147, 148 . Advanced MRI can detect subtle changes in brain activity and morphology that is related to impairments in cognitive or emotional function even in mild clinical TBI 149, 150 and in animal models of TBI 147, 151, 152 . Despite notable advances in diagnostic neuroimaging, accurate and early evaluation of the severity of TBI and prediction of long-term outcomes are difficult. This calls for a concerted effort to search for sensitive and reliable biomarkers of TBI. Unique biochemical, neuroimaging and genetic biomarkers may exist and can be identified in response to different injury severities and different types of injuries. To ensure biomarkers in animal models of TBI genuinely reflect those associated with TBI in humans, the biomarkers measured in humans with TBI should also be measured in TBI animals and vice versa, so that clinically relevant biomarkers can be identified. A common biomarker, if identified, will facilitate translation of findings from the laboratory (for example, evaluation of the efficacy of preclinical therapeutic treatments) to the clinic.
Improving translation from animals to the clinic Rigorous testing of therapeutic approaches in animal TBI models. To improve the translation of preclinical findings into successful clinical treatments, various factors need to be considered in future preclinical studies. Before the translation of a preclinical therapy into TBI clinical trials, the prospective treatment should have been tested in multiple experiments and, preferably, in several TBI models (in small and large animals) with different injury severities. The optimal administration routes and therapeutic windows, and dose-response curves should have been determined, and treatment aspects such as single dose versus multiple dose and bolus dose versus continuous infusions should have been assessed.
The effective progression of treatment strategies into clinical trials may require multifunctional agents and/ or combination therapies. These potential combinations could include single pharmaceutical agents together with cells (for example, somatic or stem cells, or genetically modified derivatives) or other approaches (other biomaterials, or physical or electrical stimulation) to reduce secondary damage and increase neuroplasticity. Of note, the interaction of agents used in a combination therapy should be fully addressed in preclinical studies before their assessment in clinical trials. The importance of this point is illustrated by erythropoietin (EPO), which showed promise as a treatment for ischaemic stroke in small clinical trials 153 but failed in a recent stroke clinical trial in which it was combined with the thromobolytic drug tissue plasminogen activator (tPA) 154 . Recent preclinical data demonstrated that there is a previously unknown interaction of tPA with EPO, suggesting that EPO may not be suitable as a stroke treatment after tPA induces thrombolysis 155, 156 . Multiple drugs are often used to treat TBI patients with polytrauma or complications such as higher ICP, infection and seizure. This may increase the risks of potential interactions of those drugs with a drug tested in the clinical trial. Thus, preclinical studies are needed to rigorously address drug safety and efficacy to guide subsequent clinical trials, especially of combination therapies for TBI. One other point is that many agents that entered into clinical trials for TBI have been rarely assessed in pharmacokinetic and pharmacodynamic studies or in terms of brain penetration and distribution (for systemically administered drugs) in TBI models 19 . Extensive investigation of these issues is warranted in preclinical studies.
The therapeutic approach tested in preclinical studies has to reflect the clinical scenario. Neuroprotection approaches have historically been dominated by targeting neuron-based injury mechanisms, either as the primary or even exclusive focus of the therapeutic strategy 157 . In the vast majority of animal models of TBI, the prospective neuroprotective compounds have been administered either early after TBI or, frequently, before the injury is delivered 67 , which is not clinically relevant. The early administration of a compound by pre-hospital care personnel may be problematic because of the difficulty in obtaining informed consent 158 . Thus, it is eminently reasonable to test compounds that can be administered late after onset of TBI that have neurorestorative effects. The essential difference between neuroprotective and neurorestorative treatments is that the former mainly target the lesion and the latter treat the intact tissue 159 . Thus, neurorestorative treatments can be made available for targeting a larger portion of patients with TBI. It is essential to rigorously test neurorestorative therapies in addition to neuroprotective therapies in animal models of TBI
Long-term versus short-term studies. To date, most of the studies in animal models of TBI have focused primarily on short-term survival times, in the range of hours to days, and have rarely extended beyond 1 month after injury 67 . These short-term studies have provided abundant information on the pathophysiology and functional outcomes during the acute stage after TBI. The histological and behavioural data obtained at the early time points postinjury may not provide a valid assessment of the longterm outcome and cannot be used to assess clinical therapies for long-lasting efficacy. To verify whether early changes can predict the long-term outcome, more studies evaluating injury responses and functional deficits over longer time periods (from 3 months to 1 year after TBI) are warranted. A small number of experimental TBI studies have followed outcomes of animals beyond 1 month after injury 69, 70, [160] [161] [162] [163] . However, several studies have demonstrated that long-term functional and structural changes take place up to 1 year after TBI 48, 70, 160, 162 . These findings suggest that the therapeutic window may not be limited to the first few hours after TBI and may extend far beyond this period. In addition, the delayed progression of brain damage over periods of months and even years suggests that to reduce brain damage, early treatment is necessary but may not be sufficient to promote longterm recovery, and continued treatment may be needed for long-term functional recovery. Delayed treatment may benefit patients with TBI who miss the early window of neuroprotection therapy. Previous studies in animals have provided a proof-of-principle for improvement of functional recovery with delayed neurorestorative treatments that are initiated 24 hours 164, 165 or beyond 166 after TBI. Although long-term behavioural deficits can be detected in rodent models of TBI, it seems that cognitive deficits are more robust and persistent than sensorimotor deficits, and different focal impact sites produce dissociable patterns of cognitive deficits in rats 69, 167, 168 , which is consistent with the observations that cognitive deficits are the most common disabling sequelae of human TBI 67, 169 . These findings suggest that rodents can be used to model different subgroups of patients with TBI. Given that the therapeutic potential of novel treatments may be limited to specific injury types and even to specific behavioural deficits 170 , the use of various injury types and a comprehensive battery of long-term behavioural tests is highly recommended for future preclinical studies.
TBI models with comorbidities. Despite modern intensive care, death and disability in polytrauma patients with concomitant TBI remain unacceptably high 171 . TBI in the clinical setting is a heterogeneous injury featuring a combination of haematomas, contusion, DAI, subarachnoid haemorrhage, hypoxia and ischaemia, and can be accompanied by medication or substance use 5 . To better mimic clinical situations, some of these factors have been integrated into the animal TBI models. The CCI and impact acceleration models have been combined with hypoxia 172 , hypoxia and hypotension 173, 174 , and the LFPI model has been combined with hypoxia 175 and/ or hypotension 176 . These systemic insults were shown to exacerbate histological and behavioural outcomes in these models 177 . However, these factors are understudied in animal models of TBI. Further development of more clinically relevant animal models of TBI is necessary to incorporate hypoxia, ischaemia and other potentially relevant factors that influence clinical head injury to reproduce the complete pathobiology of human TBI and to test potential therapies targeting these factors.
Multiple injuries can result in a complex pathophysiological and immunological response 178 . Indeed, LFPI combined with a tibial fracture initiates a robust systemic inflammatory response in rats 179 . Pharmacological treatment should be evaluated in TBI models with multiple injuries because injury to other organs may significantly change drug biodistribution, bioavailability and metabolism, which together may affect drug efficacy and toxicity. In addition, identification of unique neurochemical mediators and mechanisms following multiple injuries will help determine effective therapeutic interventions in individual patients with TBI.
Age is another important comorbidity factor affecting outcomes in TBI. TBI is the leading cause of death in children, and survivors of childhood TBI are at risk of developing and sustaining behavioural impairments 180 .
Clinical and experimental studies demonstrate that the developing brain may be more vulnerable to traumatic injury than
Box 3 | Neuroprotection and neurorestoration
Acute neuroprotective therapies aim to block the molecular cascade of injury following traumatic brain injury (TBI). Although neuroprotection is an important strategy for the treatment of such injury 214 , to date, no effective neuroprotective agents have been identified from TBI clinical trials. The disappointing results from clinical trials may have been due to variability in the treatment approaches and heterogeneity in the injury characteristics in the TBI patient populations 188, [214] [215] [216] . Another important point is that most clinical trial strategies have used drugs that target a single pathophysiological mechanism despite the fact that many mechanisms are involved in secondary injury after TBI 215 . Testing multifunctional agents or combination therapies is an important research direction in animal models of TBI. A major limitation of neuroprotection strategies is the short time window in which to deliver the therapy; a neuroprotective treatment may only be efficacious within several minutes to hours after TBI onset.
Recent preclinical studies from our group and others have revealed that TBI induces many neurorestorative processes, including neurogenesis, axonal sprouting, synaptogenesis, oligodendrogenesis and angiogenesis, which may contribute to spontaneous functional recovery 192, [217] [218] [219] [220] [221] . In addition, treatments that promote these neurorestorative processes have been shown to improve functional recovery after brain injury 159, 222 . However, clinical trials in TBI have primarily targeted neuroprotection, and trials directed specifically at neurorestoration have not been fully investigated in animal models and are rarely conducted in patients with TBI. Unlike neuroprotection, restorative therapies are aimed at remodelling brain tissue rather than solely reducing cell death or lesion volume. Indeed, in TBI animal models neurorestorative therapy can be administered for an extended, 24-hour window and improves neurological recovery without altering cortical lesion volume 164, 223 . Thus, neurorestorative therapy could potentially have a high clinical impact. Further investigation of neurorestorative agents in animal models is warranted to increase the therapeutic window and to target an expanded population of patients with TBI.
the adult brain 181 . Animal models have shown that developmental TBI results in different acute injury responses and recovery 180, 182 . Among the developmental animal models of TBI, CCI, FPI and Marmarou's weight-drop models are most commonly used in immature rodents and pigs 180 , whereas rapid non-impact inertial head injury are used in immature pigs 127, 183 . Relative to adult TBI, our understanding and management of paediatric TBI is still in its infancy. More comprehensive studies in this area will strengthen our understanding of the complex interactions between brain maturation and recovery from injury and will provide crucial ground work for addressing unique responses of this specific age group to TBI.
With increasing age comes an increased risk for sustaining TBI 184 . Elderly individuals with TBI differ from younger adults with TBI in several ways, including their incidence rates, aetiology of injury, nature of complications, lengths of hospitalization, functional outcomes and mortality 185 . Adults older than 75 years of age have the highest rates of TBI-related hospitalization and death, with falls as the leading cause of TBI 186 . Older age is known to negatively affect outcome after TBI 187 . However, the effect of age is rarely studied in animal models. To address this important public health issue, age is an important factor to consider in preclinical efficacy studies 184, 186 . In addition, therapeutic doses of a treatment identified as being effective in young animals with TBI may have no effect on or even worsen the outcome in aged TBI rats 184 . This finding suggests that it is not sufficient to simply study the effects of age on TBI, and novel therapies must be evaluated in aged populations of animals with TBI. Given the high incidence of TBI in the aged population, much more preclinical research is needed in this area.
Conclusions and perspective
Overcoming the lack of drugs with proven clinical efficacy in TBI is a major challenge for the neuroscience research community and the pharmaceutical industry. Studies using various animal models, in vitro models and computational modelling of TBI have contributed to the current understanding of the post-traumatic sequelae. Among these approaches, animal models remain necessary to address complex physiological and pathophysiological mechanisms associated with this condition, test new therapeutic agents and ensure that clinical trials are safe and, ultimately, successful. Various rodent models of TBI have been developed to model different injury mechanisms associated with human TBI. The rodent models by Marmarou 26 and Shohami 91 are widely used for CHI and they reproduce predominantly diffuse and focal brain injury, respectively. Probably owing to excellent reproducibility, LFPI and CCI are the most widely used rodent models for TBI. There is increasing research in blast TBI and sports-related concussions, especially repeated mild TBI.
Although small animal models have been used in TBI research to investigate the basic mechanisms and pathology of TBI and to test therapeutic efficacy, successful TBI investigations in these animal models have not resulted in marked improvements in the clinical outcomes of patients with TBI. One of the major barriers to crossing the translational gap is that, owing to ethical and financial issues, researchers rarely use clinically meaningful large animal models of TBI to monitor clinically relevant physiological parameters and long-term functional and/or cognitive outcomes, and to test the efficacy of new treatments. Thus, it is extremely important to further develop and increasingly use higher species with brains that are more anatomically and functionally closer to man. At least, before initiation of clinical trials, an effective treatment in rodents should have its efficacy confirmed in large animal models that closely mimic the complex pathogenesis of TBI in humans.
Numerous promising treatment options have emerged in recent years, including neuroprotective, neurorestorative and anti-inflammatory agents 188 . These drugs should be subjected to a rigorous preclinical dose-response analysis of their efficacy on the target mechanism and the ability to reduce post-traumatic neurodegeneration and to improve behavioural and neurological recovery. This endeavour would facilitate the transition of TBI therapies from the bench to the bedside.
The failure to achieve a therapeutic breakthrough in TBI may not result only from limitations of the animal models per se. Poor clinical study design is also a factor in why therapeutic translation has not occurred. For example, early therapeutic hypothermia is beneficial in many experimental models of TBI. Hypothermia appeared to improve the outcome in patients with TBI who were undergoing craniotomy for haematoma only when hypothermia was applied before craniotomy or within 1.5 hours after craniotomy, but did not improve the outcome of patients with diffuse brain injury 189 . This implies that optimal timing of combined treatments has a crucial role in a beneficial outcome in a specific population of patients with TBI. Thus, the continued translation of new findings from the bench to the bedside and then back to the bench will ultimately teach us a lot about the relevance of our animal models. Most importantly, these types of back and forth exchange of observations and ideas will help us to determine which pathophysiological mechanisms are most important to target in specific patient populations. The lack of success of translating preclinical effective treatments to clinical TBI is complex and may result from both the multifaceted issues of suboptimal animal models and inadequate design and implementation of clinical trials, as described by us in this Review and by others 14, [190] [191] [192] [193] [194] [195] [196] . In addition, as we have discussed, the pathophysiological heterogeneity of patients with TBI, the lack of sufficient pharmacokinetic analysis for determination of optimal dose, compounds given outside of the therapeutic window and insensitive outcome measures may limit proof of clinical efficacy [193] [194] [195] [196] . The ongoing international effort to develop an improved classification system for individuals with TBI may enable the selection of more homogenous patient cohorts in future clinical trials to facilitate multicentre comparisons 195 .
In conclusion, current animal models mimic some but not all types of human brain injury. To achieve a therapeutic breakthrough in TBI will probably require a multifaceted approach combining the following: innovations in clinical trial design; the development of new clinically relevant models; refinements of established models and functional tests; consideration of systemic insults and multimodality monitoring; searching for specific and sensitive biomarkers; and optimization of therapeutic dosing and timing of single and combination treatments. In addition, more research into the effects of age, sex and species or strains on the outcome of TBI is necessary. One final important issue is that most drugs that have been tested to date cannot cross the BBB to effectively target the injured brain. Additional studies in improving brain drug delivery systems and monitoring of target drug levels and drug effects are warranted in both animal models and the clinical setting.
